Subscribe to newsletters Sign in

Pharmaceutical treatments lacking

By Denis Méthot | January 22 2020 02:39PM

The term "orphan" appeared in the early 1980s in the United States in connection with the treatment of rare diseases. It was said that a disease was orphaned if there was no treatment other than that of its symptoms.

This article is reserved to PRO Level subscribers

Read the whole article….

PRO

$9.95 / month

Invest in your career and go PRO now!:

Each of its 6 annual issues offers you:

Exclusive headlines and daily scoops
Disciplinary decision news
On the move in the industry

Receive the Insurance Journal at your office or home:

6 issues/year
In-depth articles and studies related to the insurance industry
Insighful data to feed your analysis and convince your clients
Exclusive interviews with industry leaders

Rare and orphan diseases: a challenge for individuals and society

Pharmaceutical treatments lacking

Related to the same topic …

Flash

CDPQ posts return of 10.4 per cent

Sun Life announces fund mergers

OSFI consults on new benchmark rate for uninsured mortgages

Proposed class action filed against Sun Life

Living Benefits

Rare and orphan diseases: a challenge for individuals and society

Younger workers show strong interest in virtual healthcare

Sun Life Q3 earnings up, led by higher sales in Asia

Manulife reports earnings decline in third quarter

Critical Illness

iA Financial assimilates Excellence Life

Equisoft and Humania team up on new platform to promote 5575 product

Supplementary health insurance

Digital health key to more affordable health services, says report

CLHIA asks for strategies on expensive drugs and retirement plans

Aon appoints new EVP and Health leader

Snowbird association challenges OHIP Cuts

Drug insurance

Pharmacare plan for Canadians still a question mark

Pharmaceutical company advocates for more accessible healthcare

Biosimilars: British Columbia extends transition program

Public drug plan spending on the rise

Group Insurance

Sun Life makes $560 million buy-in group annuity deal with Rio Tinto subsidiary

Consolidation trend continues

Canada Life aims to eliminate plastic drug cards

Arthur J. Gallagher acquires benefits firm

Drug Insurance

Advocate sounds alarm about the future availability of new medicines in Canada

Investing in mental health yields significant returns

SSQ offers pharmacogenetic testing to group plan members

Plan costs due to rise: Aon

Life Insurance

CSA bans DSC sales charges in all provinces – except Ontario

Younger buyers drive U.S. application activity higher in January

BMO AM launches several new ETFs

Horizons ETFs introduces three new total return funds

Medication

Health care markets poised for growth

Report on virtual health care released

Family members and friends help those with mental illness

Concern rises around smoking and vaping

Special Report

Cyberattacks: We are all at risk

The Desjardins case: a $150 million tab

Threat to the insurance industry

Insurer takes the bull by the horns